Clinical Trials Logo

Diarrhea Rotavirus clinical trials

View clinical trials related to Diarrhea Rotavirus.

Filter by:
  • None
  • Page 1

NCT ID: NCT04658914 Active, not recruiting - Diarrhea Clinical Trials

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Start date: April 15, 2021
Phase: Phase 2
Study type: Interventional

Despite the widespread introduction of vaccines against Rotavirus, Rotavirus continues to be a cause of significant morbidity and mortality in the developing world. This study will assess protection against rotavirus infection and investigate immune correlates of protection following vaccination with a novel trivalent VP8 subunit rotavirus vaccine used alone or in combination with oral rotavirus vaccine.

NCT ID: NCT03703336 Completed - Diarrhea Clinical Trials

Phase III Study of Liquid Formulation of ROTAVIN

Start date: March 16, 2019
Phase: Phase 3
Study type: Interventional

This study is conducted to demonstrate non-inferiority in the immunogenicity of the liquid formulation of ROTAVIN in comparison to currently licensed frozen formulation of the vaccine (ROTAVIN-M1), 28 days after the second vaccination when administered as two dose series starting at 2-3 months of age. The study will also assess the reactogenicity of the vaccine 7 days after each vaccination and safety from first vaccination up to 4 weeks after the last vaccination.

NCT ID: NCT03602053 Completed - Diarrhea Clinical Trials

Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia

ROTAVAC
Start date: January 22, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The study is being conducted to evaluate and compare the immunogenicity of ROTAVAC® and ROTAVAC 5D 28 days after the last dose of the vaccine, when administered to infants in a three-dose schedule at 6, 10 and 14 weeks of age. The study will also assess the reactogenicity of the vaccine 7 days after each vaccination and safety from first vaccination up to 4 weeks after the last vaccination with ROTAVAC® and ROTAVAC 5D, and of Rotarix® when administered to infants in a two-dose schedule at 6 and 10 weeks of age.

NCT ID: NCT02286895 Completed - Diarrhea Rotavirus Clinical Trials

Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali

Start date: October 2014
Phase: Phase 4
Study type: Interventional

This study is an evaluation of the immune response to pentavalent rotavirus vaccine (PRV) after an additional fourth dose is given at 9 months of age with local World Health Organization (WHO) Expanded Programme on Immunization (EPI) vaccines in Mali.